Cantor Fitzgerald Forecasts ALX Oncology FY2025 Earnings

ALX Oncology Holdings Inc. (NASDAQ:ALXO - Free Report) - Investment analysts at Cantor Fitzgerald issued their FY2025 earnings estimates for shares of ALX Oncology in a report released on Tuesday, January 21st. Cantor Fitzgerald analyst L. Watsek expects that the company will earn ($2.21) per share for the year. Cantor Fitzgerald has a "Overweight" rating on the stock. The consensus estimate for ALX Oncology's current full-year earnings is ($2.76) per share.

A number of other research analysts have also commented on the company. HC Wainwright cut their price target on ALX Oncology from $25.00 to $5.00 and set a "buy" rating for the company in a report on Friday. Jefferies Financial Group lowered shares of ALX Oncology from a "buy" rating to a "hold" rating and lowered their price target for the company from $12.00 to $2.00 in a report on Thursday, December 19th. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $3.50.

ALX Oncology Stock Down 7.1 %

Shares of ALXO traded down $0.12 during trading hours on Thursday, hitting $1.52. 1,476,694 shares of the company were exchanged, compared to its average volume of 1,267,941. The firm's 50 day moving average is $1.61 and its 200-day moving average is $2.42. The company has a debt-to-equity ratio of 0.07, a quick ratio of 4.82 and a current ratio of 4.82. ALX Oncology has a 52 week low of $1.19 and a 52 week high of $17.83. The company has a market cap of $79.90 million, a PE ratio of -0.51 and a beta of 0.98.

Institutional Trading of ALX Oncology

A number of hedge funds have recently made changes to their positions in ALXO. SG Americas Securities LLC lifted its holdings in ALX Oncology by 33.6% during the 3rd quarter. SG Americas Securities LLC now owns 27,394 shares of the company's stock worth $50,000 after purchasing an additional 6,888 shares during the last quarter. Hsbc Holdings PLC acquired a new stake in shares of ALX Oncology during the second quarter worth $63,000. GSA Capital Partners LLP bought a new stake in shares of ALX Oncology in the third quarter valued at about $88,000. Barclays PLC boosted its holdings in ALX Oncology by 243.6% in the 3rd quarter. Barclays PLC now owns 59,502 shares of the company's stock valued at $107,000 after purchasing an additional 42,185 shares during the period. Finally, AQR Capital Management LLC boosted its stake in shares of ALX Oncology by 50.7% in the second quarter. AQR Capital Management LLC now owns 18,079 shares of the company's stock valued at $109,000 after buying an additional 6,080 shares during the period. 97.97% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other ALX Oncology news, Director Rekha Hemrajani purchased 30,000 shares of the company's stock in a transaction dated Monday, December 2nd. The shares were bought at an average price of $1.55 per share, with a total value of $46,500.00. Following the completion of the transaction, the director now directly owns 33,000 shares in the company, valued at $51,150. This trade represents a 1,000.00 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Over the last quarter, insiders have sold 14,443 shares of company stock worth $23,309. Insiders own 33.40% of the company's stock.

About ALX Oncology

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.